Stockscreener 앱 받기
39.19
2.56%
-1.03
시간 외 거래:
39.19
Teva Pharmaceutical Industries Ltd Adr 주식(TEVA)의 최신 뉴스
Teva Pharmaceutical Industries Limited (TEVA) Stock Price, News, Quote & History - Yahoo! Finance Canada
Teva Pharmaceutical Industries Limited (TEVA) stock price, news, quote and history - uk.finance.yahoo.com
Teva Releases Q3 2026 Aide Memoire - GlobeNewswire Inc.
Teva stock hits 52-week high at $39.71 - Investing.com
TEVA Stock Price and Chart — TASE:TEVA - TradingView
ETFs Investing in Teva Pharmaceutical Industries Limited Sponsored ADR Stocks - TradingView
TEVA Stock Quote Price and Forecast - CNN
Teva plans senior notes offering to refinance existing debt By Investing.com - Investing.com Canada
TEVA Stock Price, Quote & Chart - ChartMill
Trump's MFN Push Goes Beyond Big Pharma, Adds 9 Mid-Sized Drugmakers - TradingView
Teva announces commitment with Trump administration on Medicaid drug pricing By Investing.com - Investing.com South Africa
Teva Announces Proposed Acquisition of a Novel Neuroscience Product Reinforcing Disciplined Business Development Approach Under Pivot to Growth Strategy - Sahm
Teva Pharma Industries Ltd ADR (TEVA) Shareholding Pattern – Promoters, FIIs & DIIs - Value Research
Teva stock hits 52-week high at 37.84 USD By Investing.com - Investing.com Australia
Teva Pharmaceutical Industries (TEVA) Could Be 10% Undervalued After FDA Accepted Ecopipam NDA - sahmcapital.com
Teva (TEVA) Wins FDA Priority Review For Pediatric Tourette Drug Candidate - Sahm
Teva receives FDA priority review for Tourette drug - grafa.com
Teva Pharmaceutical’s stock is near its yearly high; is it still a buy? - Investing.com Nigeria
TEVA PHARMACEUTICAL INDUSTRIES LTD SEC Filing (Aug 17, 2026) - Stock Titan
Teva stock hits 52-week high at 37.35 USD By Investing.com - Investing.com Nigeria
Teva stock hits 52-week high at 37.35 USD - Investing.com
Moody’s upgrades Teva rating to investment grade on debt cuts By Investing.com - Investing.com Canada
Teva Pharmaceutical Industries (TEVA) Lifts Outlook On Earnings As Valuation Debate Stays Open - Sahm
Teva (TEVA) Is Up 8.8% After Raising 2026 Guidance And Highlighting Innovative Drug Momentum - Sahm
Dear Teva Pharmaceutical Stock Fans, Mark Your Calendars for September 14 - Yahoo Finance
Teva Earnings: Innovation Engine Continues Firing and Supports Our Increased Moat Rating - Morningstar
July 2026's Top Stock Selections Estimated Below Intrinsic Value - Sahm
Teva Pharmaceutical Industries (TEVA) Raises Revenue Guidance, Is The 15% Undervaluation Still There? - Sahm
Earnings call transcript: Teva’s Q2 2026 revenue beats, shares rise premarket - Investing.com
Why Is Teva (NYSE:TEVA) Making NYSE Composite Headlines? - Kalkine Media
Daily Brief Health Care: Apnimed, Chugai Pharmaceutical, Equifax Inc, Royalty Pharma , Startline, Surgery Partners, Teva Pharmaceutical Sp Adr, Thermo Fisher Scientific Inc and more - Smartkarma
Teva Pharmaceutical Industries Limited Sponsored ADR Revenue Breakdown – BX:TEV - TradingView
Does Teva Pharmaceutical Industries (NYSE:TEVA) Still Look Undervalued After A 260% Run? - Sahm
What Teva Pharmaceutical Industries (TEVA)'s TEV‑408 Vitiligo Data and Funding Deal Means For Shareholders - Sahm
MINT,TEVA Volatility & Greeks - Finviz
Teva Pharmaceutical Industries (TEVA) Advances TEV 408, Is The Stock Still Cheap? - Sahm
Teva (TEVA) Stock Looks Reasonable Even With A 48% Gap - Sahm
Teva (TEVA) Advances TEV 408 Into Phase 2b For Vitiligo After Early Progress - Sahm
0.43%
자본화:
|
볼륨(24시간):